Skip to main content

Table 1 Neutralization of Stx2-mediated HeLa cell cytotoxicity by Stx2 A subunit-specific HuMAbs.

From: In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2

Neutralization groups1

HuMAb

Percent neutralization (mean ± SD) at different HuMAb doses

  

10 μg/ml

1.25 μg/ml

0.156 μg/ml

High

5C12

97 ± 1.7a

89 ± 4.1a

73 ± 5.1a

 

3E9

94 ± 3.3ab

80 ± 6.5ab

52 ± 5.3ab

 

2F10

89 ± 4.6b

71 ± 7.6b

50 ± 4.2b

Medium

7C4

69 ± 6.5c

52 ± 6.2c

38 ± 4.1c

 

6D8

68 ± 9.6c

48 ± 8.5c

38 ± 3.2c

 

9H9

65 ± 10.6c

48 ± 7.4c

29 ± 5.9cd

 

6H7

64 ± 7.1c

46 ± 6.5c

22 ± 4.5d

 

14C12

63 ± 6.8c

39 ± 7.4cd

29 ± 8.8cd

 

5E12

59 ± 9.0cd

36 ± 6.4cd

17 ± 4.6de

 

6B7

57 ± 6.2cd

37 ± 5.5cd

23 ± 3.6d

 

6H5

57 ± 5.9cd

39 ± 3.5cd

25 ± 3.9d

 

6C3

50 ± 7.1de

37 ± 5.1cd

16 ± 3.6de

 

1G1

46 ± 7.3de

27 ± 7.5d

15 ± 1.9de

Low

4H10

40 ± 8.5ef

13 ± 5.3e

10 ± 5.3e

 

5F2

35 ± 4.7f

13 ± 5.5e

1 ± 0.7f

 

6E6

34 ± 5.6f

25 ± 6.1d

9 ± 4.6e

 

3A2

31 ± 8.1fg

15 ± 8.1e

14 ± 9.1de

 

7F2

25 ± 4.7g

14 ± 7.8e

7 ± 5.1e

 

1G12

15 ± 4.7h

11 ± 5.9e

10 ± 5.5e

Placebo control

IgG1κ

5 ± 3.8h

5 ± 1.7e

2 ± 1.5f

  1. 1The HuMAbs were assigned to high (5C12, 3E9 and 2F10), medium (7C4, 6D8, 9H9, 6H7, 14C12, 5E12, 6B7, 6H5, 6C3 and 1G1) or low (4H10, 5F2, 6E6, 3A2, 7F2 and 1G12) neutralizing groups based on their abilities to neutralize Stx2-mediated HeLa cell cytotoxicity.
  2. a-hValues within a column with different superscripts are significantly (P < 0.05) different.